The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pre-Implantation Genetic Diagnosis (PGD) Market Research Report 2025
Synopsis
Pre-Implantation Genetic Diagnosis (PGD) is the genetic profiling of embryos prior to implantation (as a form of embryo profiling), and sometimes even of oocytes prior to fertilization.
The global Pre-Implantation Genetic Diagnosis (PGD) market was valued at US$ 101.7 million in 2023 and is anticipated to reach US$ 137.1 million by 2030, witnessing a CAGR of 4.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pre-Implantation Genetic Diagnosis (PGD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pre-Implantation Genetic Diagnosis (PGD).
Report Scope
The Pre-Implantation Genetic Diagnosis (PGD) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pre-Implantation Genetic Diagnosis (PGD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pre-Implantation Genetic Diagnosis (PGD) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Genea Limited
Quest Diagnostics
Illumina, Inc.
Natera, Inc.
Cooper Medical, Inc.
LabCorp
California Pacific Medical Center (CPMC)
Thermo Fisher Scientific Inc.
IGENOMIX
Reproductive Genetic Innovations
CombiMatrix
Segment by Type
Chromosomal Abnormalities
X-linked Diseases
Freeze Embryo Testing
Aneuploidy Screening
HLA
Others
Segment by Application
Stem Cell Therapy
IVF Prognosis
Late-Onset Genetic Disorders
Inherited Genetic Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pre-Implantation Genetic Diagnosis (PGD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Pre-Implantation Genetic Diagnosis (PGD) is the genetic profiling of embryos prior to implantation (as a form of embryo profiling), and sometimes even of oocytes prior to fertilization.
The global Pre-Implantation Genetic Diagnosis (PGD) market was valued at US$ 101.7 million in 2023 and is anticipated to reach US$ 137.1 million by 2030, witnessing a CAGR of 4.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pre-Implantation Genetic Diagnosis (PGD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pre-Implantation Genetic Diagnosis (PGD).
Report Scope
The Pre-Implantation Genetic Diagnosis (PGD) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pre-Implantation Genetic Diagnosis (PGD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pre-Implantation Genetic Diagnosis (PGD) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Genea Limited
Quest Diagnostics
Illumina, Inc.
Natera, Inc.
Cooper Medical, Inc.
LabCorp
California Pacific Medical Center (CPMC)
Thermo Fisher Scientific Inc.
IGENOMIX
Reproductive Genetic Innovations
CombiMatrix
Segment by Type
Chromosomal Abnormalities
X-linked Diseases
Freeze Embryo Testing
Aneuploidy Screening
HLA
Others
Segment by Application
Stem Cell Therapy
IVF Prognosis
Late-Onset Genetic Disorders
Inherited Genetic Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pre-Implantation Genetic Diagnosis (PGD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pre-Implantation Genetic Diagnosis (PGD) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Chromosomal Abnormalities
1.2.3 X-linked Diseases
1.2.4 Freeze Embryo Testing
1.2.5 Aneuploidy Screening
1.2.6 HLA
1.2.7 Others
1.3 Market by Application
1.3.1 Global Pre-Implantation Genetic Diagnosis (PGD) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Stem Cell Therapy
1.3.3 IVF Prognosis
1.3.4 Late-Onset Genetic Disorders
1.3.5 Inherited Genetic Disease
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pre-Implantation Genetic Diagnosis (PGD) Market Perspective (2019-2030)
2.2 Pre-Implantation Genetic Diagnosis (PGD) Growth Trends by Region
2.2.1 Global Pre-Implantation Genetic Diagnosis (PGD) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Pre-Implantation Genetic Diagnosis (PGD) Historic Market Size by Region (2019-2024)
2.2.3 Pre-Implantation Genetic Diagnosis (PGD) Forecasted Market Size by Region (2025-2030)
2.3 Pre-Implantation Genetic Diagnosis (PGD) Market Dynamics
2.3.1 Pre-Implantation Genetic Diagnosis (PGD) Industry Trends
2.3.2 Pre-Implantation Genetic Diagnosis (PGD) Market Drivers
2.3.3 Pre-Implantation Genetic Diagnosis (PGD) Market Challenges
2.3.4 Pre-Implantation Genetic Diagnosis (PGD) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pre-Implantation Genetic Diagnosis (PGD) Players by Revenue
3.1.1 Global Top Pre-Implantation Genetic Diagnosis (PGD) Players by Revenue (2019-2024)
3.1.2 Global Pre-Implantation Genetic Diagnosis (PGD) Revenue Market Share by Players (2019-2024)
3.2 Global Pre-Implantation Genetic Diagnosis (PGD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pre-Implantation Genetic Diagnosis (PGD) Revenue
3.4 Global Pre-Implantation Genetic Diagnosis (PGD) Market Concentration Ratio
3.4.1 Global Pre-Implantation Genetic Diagnosis (PGD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pre-Implantation Genetic Diagnosis (PGD) Revenue in 2023
3.5 Pre-Implantation Genetic Diagnosis (PGD) Key Players Head office and Area Served
3.6 Key Players Pre-Implantation Genetic Diagnosis (PGD) Product Solution and Service
3.7 Date of Enter into Pre-Implantation Genetic Diagnosis (PGD) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pre-Implantation Genetic Diagnosis (PGD) Breakdown Data by Type
4.1 Global Pre-Implantation Genetic Diagnosis (PGD) Historic Market Size by Type (2019-2024)
4.2 Global Pre-Implantation Genetic Diagnosis (PGD) Forecasted Market Size by Type (2025-2030)
5 Pre-Implantation Genetic Diagnosis (PGD) Breakdown Data by Application
5.1 Global Pre-Implantation Genetic Diagnosis (PGD) Historic Market Size by Application (2019-2024)
5.2 Global Pre-Implantation Genetic Diagnosis (PGD) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Pre-Implantation Genetic Diagnosis (PGD) Market Size (2019-2030)
6.2 North America Pre-Implantation Genetic Diagnosis (PGD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Pre-Implantation Genetic Diagnosis (PGD) Market Size by Country (2019-2024)
6.4 North America Pre-Implantation Genetic Diagnosis (PGD) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pre-Implantation Genetic Diagnosis (PGD) Market Size (2019-2030)
7.2 Europe Pre-Implantation Genetic Diagnosis (PGD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Pre-Implantation Genetic Diagnosis (PGD) Market Size by Country (2019-2024)
7.4 Europe Pre-Implantation Genetic Diagnosis (PGD) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pre-Implantation Genetic Diagnosis (PGD) Market Size (2019-2030)
8.2 Asia-Pacific Pre-Implantation Genetic Diagnosis (PGD) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Pre-Implantation Genetic Diagnosis (PGD) Market Size by Region (2019-2024)
8.4 Asia-Pacific Pre-Implantation Genetic Diagnosis (PGD) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pre-Implantation Genetic Diagnosis (PGD) Market Size (2019-2030)
9.2 Latin America Pre-Implantation Genetic Diagnosis (PGD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Pre-Implantation Genetic Diagnosis (PGD) Market Size by Country (2019-2024)
9.4 Latin America Pre-Implantation Genetic Diagnosis (PGD) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pre-Implantation Genetic Diagnosis (PGD) Market Size (2019-2030)
10.2 Middle East & Africa Pre-Implantation Genetic Diagnosis (PGD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Pre-Implantation Genetic Diagnosis (PGD) Market Size by Country (2019-2024)
10.4 Middle East & Africa Pre-Implantation Genetic Diagnosis (PGD) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Pre-Implantation Genetic Diagnosis (PGD) Introduction
11.1.4 Roche Revenue in Pre-Implantation Genetic Diagnosis (PGD) Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Genea Limited
11.2.1 Genea Limited Company Detail
11.2.2 Genea Limited Business Overview
11.2.3 Genea Limited Pre-Implantation Genetic Diagnosis (PGD) Introduction
11.2.4 Genea Limited Revenue in Pre-Implantation Genetic Diagnosis (PGD) Business (2019-2024)
11.2.5 Genea Limited Recent Development
11.3 Quest Diagnostics
11.3.1 Quest Diagnostics Company Detail
11.3.2 Quest Diagnostics Business Overview
11.3.3 Quest Diagnostics Pre-Implantation Genetic Diagnosis (PGD) Introduction
11.3.4 Quest Diagnostics Revenue in Pre-Implantation Genetic Diagnosis (PGD) Business (2019-2024)
11.3.5 Quest Diagnostics Recent Development
11.4 Illumina, Inc.
11.4.1 Illumina, Inc. Company Detail
11.4.2 Illumina, Inc. Business Overview
11.4.3 Illumina, Inc. Pre-Implantation Genetic Diagnosis (PGD) Introduction
11.4.4 Illumina, Inc. Revenue in Pre-Implantation Genetic Diagnosis (PGD) Business (2019-2024)
11.4.5 Illumina, Inc. Recent Development
11.5 Natera, Inc.
11.5.1 Natera, Inc. Company Detail
11.5.2 Natera, Inc. Business Overview
11.5.3 Natera, Inc. Pre-Implantation Genetic Diagnosis (PGD) Introduction
11.5.4 Natera, Inc. Revenue in Pre-Implantation Genetic Diagnosis (PGD) Business (2019-2024)
11.5.5 Natera, Inc. Recent Development
11.6 Cooper Medical, Inc.
11.6.1 Cooper Medical, Inc. Company Detail
11.6.2 Cooper Medical, Inc. Business Overview
11.6.3 Cooper Medical, Inc. Pre-Implantation Genetic Diagnosis (PGD) Introduction
11.6.4 Cooper Medical, Inc. Revenue in Pre-Implantation Genetic Diagnosis (PGD) Business (2019-2024)
11.6.5 Cooper Medical, Inc. Recent Development
11.7 LabCorp
11.7.1 LabCorp Company Detail
11.7.2 LabCorp Business Overview
11.7.3 LabCorp Pre-Implantation Genetic Diagnosis (PGD) Introduction
11.7.4 LabCorp Revenue in Pre-Implantation Genetic Diagnosis (PGD) Business (2019-2024)
11.7.5 LabCorp Recent Development
11.8 California Pacific Medical Center (CPMC)
11.8.1 California Pacific Medical Center (CPMC) Company Detail
11.8.2 California Pacific Medical Center (CPMC) Business Overview
11.8.3 California Pacific Medical Center (CPMC) Pre-Implantation Genetic Diagnosis (PGD) Introduction
11.8.4 California Pacific Medical Center (CPMC) Revenue in Pre-Implantation Genetic Diagnosis (PGD) Business (2019-2024)
11.8.5 California Pacific Medical Center (CPMC) Recent Development
11.9 Thermo Fisher Scientific Inc.
11.9.1 Thermo Fisher Scientific Inc. Company Detail
11.9.2 Thermo Fisher Scientific Inc. Business Overview
11.9.3 Thermo Fisher Scientific Inc. Pre-Implantation Genetic Diagnosis (PGD) Introduction
11.9.4 Thermo Fisher Scientific Inc. Revenue in Pre-Implantation Genetic Diagnosis (PGD) Business (2019-2024)
11.9.5 Thermo Fisher Scientific Inc. Recent Development
11.10 IGENOMIX
11.10.1 IGENOMIX Company Detail
11.10.2 IGENOMIX Business Overview
11.10.3 IGENOMIX Pre-Implantation Genetic Diagnosis (PGD) Introduction
11.10.4 IGENOMIX Revenue in Pre-Implantation Genetic Diagnosis (PGD) Business (2019-2024)
11.10.5 IGENOMIX Recent Development
11.11 Reproductive Genetic Innovations
11.11.1 Reproductive Genetic Innovations Company Detail
11.11.2 Reproductive Genetic Innovations Business Overview
11.11.3 Reproductive Genetic Innovations Pre-Implantation Genetic Diagnosis (PGD) Introduction
11.11.4 Reproductive Genetic Innovations Revenue in Pre-Implantation Genetic Diagnosis (PGD) Business (2019-2024)
11.11.5 Reproductive Genetic Innovations Recent Development
11.12 CombiMatrix
11.12.1 CombiMatrix Company Detail
11.12.2 CombiMatrix Business Overview
11.12.3 CombiMatrix Pre-Implantation Genetic Diagnosis (PGD) Introduction
11.12.4 CombiMatrix Revenue in Pre-Implantation Genetic Diagnosis (PGD) Business (2019-2024)
11.12.5 CombiMatrix Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
